CIK-Tumor Cells Cytotoxicity Analysis Service

CIK Therapy

CIK cells represent a heterogeneous group of highly proliferative, cytotoxic NK-like T lymphocytes derived from peripheral blood mononuclear cells (PBMCs). These cells are heterogeneous, consisting of a mix of different cell populations, including CD3+CD56− T cells, CD3−CD56+ natural killer (NK) cells, and the hybrid CD3+CD56+ natural killer T (NKT) cells. The cytotoxic activity of CIK cells is chiefly facilitated through direct recognition and binding to tumor antigens, a process enhanced by their expression of both T-cell receptors and NK cell-associated markers such as NKG2D. This enables CIK cells to bypass major histocompatibility complex (MHC) restrictions, thereby effectively recognizing a broad spectrum of tumor cells. Upon engagement with target cells, CIK cells release cytotoxic granules containing perforin and granzymes, which perforate the tumor cell membrane, inducing apoptosis. In addition to direct killing, CIK cells secrete pro-inflammatory cytokines, enhancing the recruitment and activation of other immune cells to the tumor site.

CIK cells exhibit unique advantages, including:

• High proliferative capacity
• Broad-spectrum cytotoxicity against tumor cells
• Minimal side effects on normal tissues

Fig.1 CIK therapy.¹

CIK-Tumor Cells Cytotoxicity Services

At Creative Biolabs, we provide a comprehensive CIK-tumor cells cytotoxicity analysis service, designed to meticulously evaluate the cytotoxic capabilities of CIK cells against tumor cells. We cultivate CIK cells under optimal conditions to ensure their peak performance in cytotoxicity. Subsequently, these cells are co-cultured with the selected tumor cell lines at various effector/target (E/T) ratios over set cultivation periods. Various assays are then employed to measure the resulting cytotoxic effects. This comprehensive service not only provides detailed insights into the functional capabilities of CIK cells but also aids in customizing therapies tailored to target specific types of tumors. Whether for research or clinical applications, our cytotoxicity analysis service provides you with the data needed to make informed decisions regarding the use of CIK cells in combating cancer.

Our Methods

Our team employs state-of-the-art techniques to quantify the cytotoxic activity of CIK cells.

• LDH Assay

This assay measures the release of LDH enzyme from damaged cells. This is typically used as an indicator of cell membrane integrity, which is compromised during cytotoxic events.

• Flow Cytometry-Based Assays

Flow Cytometry can determine cell viability using dyes that label dead cells or living cells. In addition, the expression of crucial cytotoxic molecules such as NKG2D, NK1.1, perforin, FasL, and granzyme B is monitored using flow cytometry. This analysis helps in understanding the mechanisms through which CIK cells exert their antitumor effects.

• Chromium-51 (⁵¹Cr) Release Assay

This assay is a classic method for assessing cell-mediated cytotoxicity by labeling target cells with radioactive chromium-51. Upon lysis by cytotoxic cells, the ⁵¹Cr is released into the supernatant and measured.

• Colorimetric Assays

Several colorimetric assays like CCK-8, XTT and MTT assays measure cell metabolic activity. Colorimetric assays are convenient because they are relatively simple, cost-effective, and allow high-throughput screening.

Key Advantages of Our Service

• Customizable Experimental Design
• High Sensitivity and Accuracy
• Expertise and Support
• State-of-the-Art Technology

Partner with Creative Biolabs

At Creative Biolabs, we are committed to accelerating cancer research by delivering superior cytotoxicity analysis services. Our comprehensive service meticulously evaluates the cytotoxic strengths of CIK cells against diverse tumor types. Our experts are dedicated to delivering reliable and reproducible results tailored to your project needs. Contact Creative Biolabs today for more information or to discuss your project requirements.

Reference

1. Introna, Martino, and Fabio Correnti. "Innovative clinical perspectives for CIK cells in cancer patients." International journal of molecular sciences 19.2 (2018): 358. Distributed under Open Access license CC BY 4.0, without modification.